Targeting specific brain cells to improve treatment for Parkinson's disease
Cell-type Specific Neuromodulation Using Burst DBS Produces Long-lasting Behavioral and Physiological Rescue in a Parkinsonian Mouse Model
This study is looking at a new way to use deep brain stimulation for people with Parkinson's disease by trying out a different pattern of stimulation that might help improve movement and quality of life without causing as many side effects.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Carnegie-Mellon University NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10904861 on NIH RePORTER |
What this research studies
This research investigates a new approach to deep brain stimulation (DBS) for Parkinson's disease by focusing on specific types of brain cells. Instead of delivering continuous stimulation, which can lead to side effects, the study explores burst stimulation patterns that may provide longer-lasting benefits. By using advanced techniques to manipulate certain neuronal populations, the research aims to enhance the effectiveness of DBS while reducing the need for constant stimulation. This could lead to improved motor function and quality of life for patients suffering from Parkinson's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease who experience motor symptoms that are not adequately controlled by medication.
Not a fit: Patients who do not have Parkinson's disease or those whose symptoms are well-managed with current treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with Parkinson's disease.
How similar studies have performed: Other research has shown promise in using targeted stimulation techniques for neurological disorders, suggesting potential for success in this novel approach.
Where this research is happening
Pittsburgh, United States
- Carnegie-Mellon University — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Nanivadekar, Shruti — Carnegie-Mellon University
- Study coordinator: Nanivadekar, Shruti
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.